Patient-Reported Side Effects of Intradetrusor Botulinum Toxin Type A for Idiopathic Overactive Bladder Syndrome

Abstract

Objective: The aim of the study was a prospective assessment of patient-reported side effects in an open-label study after intradetrusor botulinum toxin injections for idiopathic overactive bladder (OAB). Patients and Methods: Botulinum toxin A injection was performed in 56 patients with idiopathic OAB. Patients were followed up for 6 months concerning side effects and patients’ satisfaction. Results: Different types of side effects were assessed such as dry mouth (19.6%), arm weakness (8.9%), eyelid weakness (8.9%), leg weakness (7.1%), torso weakness (5.4%), impaired vision (5.4%) and dysphagia (5.4%). In all cases, symptoms were mild and transient. Urological complications such as gross hematuria (17.9%), acute urinary retention (8.9%) and acute urinary tract infection (7.1%) were noticed. In all cases, acute urinary retention was transient and treated with temporary intermittent self-catheterization. There was no statistically significant correlation between dosage and observed side effects. Patients’ satisfaction rate was high (71.4%). Conclusion: Intradetrusor injection of botulinum toxin was associated with a high rate of neurourological side effects. In general, side effects were transient, mild and did not require special treatment.

Submucosal Administration of OnabotulinumtoxinA in the Treatment of Neurogenic Detrusor Overactivity: Pilot Single-Centre Experience and Comparison with Standard Injection into the Detrusor

“…This weakness, which subsided spontaneously within 24 h, was of light intensity and did not require treatment. Bauer et al [20] reported neurological side effects after treatment of idiopathic detrusor overactivity: 7.1% of patients reported leg weakness, 5.4% reported torso weakness and 8.9% reported arm weakness. In general, all side effects were transient and did not require treatment.…”

Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB

“…Most of these studies assessed satisfaction at a single time point (e.g., months after treatment) [25,27]. In addition, a single item was often the sole measurement of satisfaction [16,28].…”

“…Others were often open-label studies that did not allow for a comparison with a control group [28]. The current study has several advantages over the previous studies that evaluated satisfaction with botulinum toxin A, including a larger patient population, inclusion of a placebo-control group for direct comparison, and the assessment of treatment satisfaction over a range of onabotulinumtoxinA study doses.…”

OnabotulinumtoxinA in the treatment of neurogenic bladder

“…However, it must be noted that the majority of cases of hypoasthenia are transient and mild. There are no reports of adults requiring hospitalization and only a few reports of significant disruption to patient quality of life 44,48,49…”